Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.
If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.
StrongSupportsVERY_HIGH confidence
The SELECT trial provided compelling evidence that semaglutide reduced MACE by 20% in individuals without diabetes who are overweight or obese... The STEP trials demonstrated that semaglutide induces substantial and sustained weight loss.
Why this rating
Supported by large, landmark RCTs (LEADER, SUSTAIN-6, SELECT, STEP).
Source
Expanding the Role of Novel Therapeutics in Cardiometabolic Syndrome: Beyond Heart Failure and Diabetes
Hyun‐Jin Kim · CardioMetabolic Syndrome Journal · 2025
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →